Treatment of elderly patients (pts; > 75 years) with 1st-line ribociclib (RIB) plus endocrine therapy (ET) or endocrine monotherapy in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))

T Decker, C Brucker, P Fasching, T Göhler, C Jackisch, J Janssen, A Koehler, K Luedtke-Heckenkamp, D Lüftner, M Van Mackelenbergh, F Marmé, A Nusch, B Rautenberg, T Reimer, M Schmidt, R Weide, P Wimberger, SM Figueroa, C Roos, A Woeckel

Research output: Contribution to journalpublished Abstract (Journal)peer-review

Original languageEnglish
Pages (from-to)S354-S355
JournalANNALS OF ONCOLOGY
Volume34
DOIs
Publication statusPublished - 2023

Cite this